Brief: FDA Approves Freenome’S Simplescreen™ Crc Blood-Based Screening Test Abbott To Commercialize In The U.S.
27/07/2026 13:09
BRIEF-FDA Approves Freenome’S Simplescreen™ Crc Blood-Based Screening Test Abbott To Commercialize In The U.S. July 27 (Reuters) - Perceptive Capital Solutions Corp FRNM.O:
FDA APPROVES FREENOME’S SIMPLESCREEN™ CRC BLOOD-BASED SCREENING TEST; ABBOTT TO COMMERCIALIZE IN THE U.S.
FREENOME- FREENOME TO RECEIVE $100 MILLION MILESTONE PAYMENT FROM ABBOTT FOR FDA APPROVAL
Source text: ID:nGNXr18mG
Further company coverage: FRNM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbott Laboratories
See all newsBrief: Abbott Announces Availability Of Panbio Covid-19/Flu A&B Self-Test In Canada
Perrigo to sell infant formula business to MeridianMade for up to $175 million
Brief: Abbott Initiates Pivotal Trial For Cephea™ Device, An Innovative Treatment For Mitral Heart Valve Disease
Corrected: German startup NVision shows new path to quantum computing chips in Nature paper
Brief: Abbott Receives FDA Approval For First Device To Treat Leaks After Heart Valve Replacement